- AIM: To evaluate the radiographic response and anti-cancer efficacy of intravenous vinorelbine for pulmonary metastasis in dogs with naturally occurring malignant neoplasia.
Your dog may be qualified if:
- Dogs who have been cytologically and/or histologically diagnosed with malignant neoplasia with radiographic evidence of lung metastasis (spread) by a board-certified radiologist.
- Dogs who have been receiving non-steroidal anti-inflammatory drugs (NSAIDs) for a variety reason at least for two months prior to enrollment of this study.
- Dogs who have a wash-out period of two weeks from other oncological treatment(s) prior to this clinical trial.
If you agree to participate, your pet will receive up to 8 doses of intravenous (IV) vinorelbine chemotherapy. This chemotherapy will be given once a week for 4 doses, then once every other week for 4 more doses.
All treatments must be completed at Iowa State University. Vinorelbine chemotherapy is given IV into a vein in one of the legs. Blood work will be obtained prior to each treatment. At vinorelbine treatment #1, #4 and #8, chest x-rays will be performed to evaluation the chemotherapy efficacy.
We request that your dog’s body be returned to ISU for necropsy to confirm the definitive diagnosis of pulmonary nodules by histopathology at the time of death or humane euthanasia.
This study will receive the following free-of-charge:
- All pretreatment blood work at ISU
- Up to 8 doses of vinorelbine
- Up to 8 doses of chemotherapy administration fee
- Up to 8 doses of chemotherapy administration supply fee
You will continue to be responsible for all the following
- Chest x-rays for this clinical trial
- Other diagnostic tests if recommended
- Costs associated with the normal course of cancer diagnosis
- Treatment of any complications that may arise
- Treatment of unrelated medical conditions
- Visit charges at ISU
- Costs associated with euthanasia
Oncology Service at 515-294-4900